LY4170156 在选定的晚期实体瘤参与者中的研究
一项首次人体 1a/1b 期试验,旨在评估 LY4170156(一种针对表达叶酸受体 α 的肿瘤细胞的抗体药物偶联物)在选定的晚期实体瘤参与者中的安全性、耐受性和初步疗效
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 电话号码:1-317-615-4559
- 邮箱:LillyTrials@Lilly.com
研究联系人备份
- 姓名:Physicians interested in becoming principal investigators please contact
- 邮箱:clinical_inquiry_hub@lilly.com
学习地点
-
-
-
Milan、意大利、20141
- 招聘中
- Istituto Europeo di Oncologia
-
首席研究员:
- Giuseppe Curigliano
-
接触:
- 电话号码:+39 02 5748 9599
-
Milan、意大利、20159
- 招聘中
- Humanitas San Pio X
-
首席研究员:
- Domenica Lorusso
-
-
-
-
-
Shizuoka、日本、411-8777
- 招聘中
- Shizuoka Cancer Center
-
接触:
- 电话号码:81120023812
-
首席研究员:
- Haruyasu Murakami
-
Tokyo、日本、104-0045
- 招聘中
- National Cancer Center Hospital
-
接触:
- 电话号码:81120023812
-
首席研究员:
- Takafumi Koyama
-
Tokyo、日本、135-8550
- 招聘中
- Cancer Institute Hospital of JFCR
-
首席研究员:
- Shigehisa Kitano
-
接触:
- 电话号码:81120023812
-
-
-
-
-
Lyon、法国、69373
- 招聘中
- Centre Leon Berard
-
首席研究员:
- Isabelle Ray-Coquard
-
接触:
- 电话号码:+33478782644
-
Saint-Herblain、法国、44805
- 招聘中
- Institut de Cancerologie de l'Ouest - site St-Herblain
-
首席研究员:
- Mario Campone
-
接触:
- 电话号码:+33 02 40 67 99 00
-
Toulouse、法国、31059
- 招聘中
- Oncopole Claudius Regaud
-
首席研究员:
- Carlos Gomez-Roca
-
-
-
-
-
Adelaide、澳大利亚、5000
- 招聘中
- Cancer Research SA
-
首席研究员:
- Meena Okera
-
QLD、澳大利亚、4101
- 招聘中
- Icon Cancer Centre South Brisbane
-
首席研究员:
- Jermaine Coward
-
-
-
-
Arizona
-
Scottsdale、Arizona、美国、85258
- 招聘中
- HonorHealth
-
接触:
- 电话号码:480-323-1350
-
首席研究员:
- Muhammad Khawaja
-
-
California
-
La Jolla、California、美国、92037
- 招聘中
- University of California, San Diego (UCSD) - Moores Cancer Center
-
首席研究员:
- Ramez Eskander
-
接触:
- 电话号码:858-657-7000
-
-
Georgia
-
Atlanta、Georgia、美国、30308
- 招聘中
- Emory University
-
首席研究员:
- Beryl Manning-Geist
-
-
Michigan
-
Grand Rapids、Michigan、美国、49546
- 招聘中
- South Texas Accelerated Research Therapeutics (START) Midwest
-
首席研究员:
- Nehal Lakhani
-
接触:
- 电话号码:616-389-1652
-
-
New York
-
Mineola、New York、美国、11501
- 招聘中
- NYU Langone Health - Long Island
-
首席研究员:
- Bhavana Pothuri
-
New York、New York、美国、10065
- 招聘中
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
-
首席研究员:
- Chrisann Kyi
-
New York、New York、美国、10016
- 招聘中
- New York University (NYU) Clinical Cancer Center
-
首席研究员:
- Bhavana Pothuri
-
接触:
- 电话号码:212-731-5100
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University (OSU) Wexner Medical Center
-
首席研究员:
- David O'Malley
-
-
Texas
-
Houston、Texas、美国、77030-4000
- 招聘中
- The University of Texas - MD Anderson Cancer Center
-
首席研究员:
- Shannon Westin
-
-
Utah
-
West Valley City、Utah、美国、84119
- 招聘中
- START Mountain Region
-
首席研究员:
- William McKean
-
-
Virginia
-
Falls Church、Virginia、美国、22042
- 尚未招聘
- Inova Schar Cancer Institute
-
首席研究员:
- Leslie Randall
-
-
-
-
-
Barcelona、西班牙、08035
- 招聘中
- Hospital Universitario Vall d'Hebron
-
接触:
- 电话号码:+34 932543450
-
首席研究员:
- Roberta Mazzeo
-
Madrid、西班牙、28041
- 招聘中
- Hospital Universitario 12 de Octubre
-
接触:
- 电话号码:+34 913908922
-
首席研究员:
- Ainhoa Madariaga Urrutia
-
Valencia、西班牙、46010
- 招聘中
- Hospital Clinico Universitario de Valencia
-
首席研究员:
- Jose Alejandro Perez Fidalgo
-
接触:
- 电话号码:+34 961973527
-
-
-
-
-
Goyang-si Gyeonggi-do、韩国、10408
- 招聘中
- National Cancer Center
-
首席研究员:
- Myong Cheol Lim
-
接触:
- 电话号码:82-1588-8110
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Have one of the following solid tumor cancers:
- Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
- Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
- Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, TNBC, and high grade endometrioid cancer
Exclusion Criteria:
- Individual with known or suspected uncontrolled central nervous system (CNS) metastases
- Individual with history of carcinomatous meningitis
- Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
- Individual with evidence of corneal keratopathy or history of corneal transplant
- Any serious unresolved toxicities from prior therapy
- Significant cardiovascular disease
- Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
- History of pneumonitis/interstitial lung disease
- Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Sofe-M (Dose-escalation, Cohort A1)
Escalating doses of Sofe-M administered intravenously (IV) |
Intravenous
其他名称:
|
|
实验性的:Sofe-M (Cohort A1 Parts A and C)
Sofe-M administered IV |
Intravenous
其他名称:
|
|
实验性的:Sofe-M Alone or with Itraconazole. Drug-Drug Interaction (DDI) (Cohort A1: Arm B)
Sofe-M administered IV and itraconazole administered orally |
Intravenous
其他名称:
oral |
|
实验性的:Sofe-M (Dose-optimization, Cohort A2)
Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV |
Intravenous
其他名称:
|
|
实验性的:Sofe-M (Enrichment Cohort A3)
Monotherapy administered IV |
Intravenous
其他名称:
|
|
实验性的:Sofe-M (Combination Cohort A4)
Combination with bevacizumab administered IV |
Intravenous
其他名称:
IV |
|
实验性的:Sofe-M (Combination Cohort A5)
Combination with carboplatin administered IV |
Intravenous
其他名称:
IV |
|
实验性的:Sofe-M Combination with Pembrolizumab (Dose-optimization Cohort A6)
Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with pembrolizumab |
Intravenous
其他名称:
IV |
|
实验性的:Sofe-M Combination with carboplatin and optional bevacizumab (Dose-optimization Cohort A7)
Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with or without bevacizumab |
Intravenous
其他名称:
IV IV |
|
实验性的:Sofe-M (Dose-expansion, Cohort B2-B4)
Sofe-M administered IV |
Intravenous
其他名称:
|
|
实验性的:Sofe-M (Dose-expansion, Cohort B1)
Sofe-M administered IV |
Intravenous
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1a: To determine the recommended phase 2 dose (RP2D) of Sofe-M (LY4170156)
大体时间:1 Cycle (21 or 28 days)
|
Number of participants with dose-limiting toxicities (DLTs) |
1 Cycle (21 or 28 days)
|
|
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with bevacizumab
大体时间:1 Cycle (21 or 28 days)
|
Number of participants with DLTs |
1 Cycle (21 or 28 days)
|
|
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with carboplatin
大体时间:1 Cycle (21 or 28 days)
|
Number of participants with DLTs |
1 Cycle (21 or 28 days)
|
|
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with pembrolizumab
大体时间:1 Cycle (21 or 28 days)
|
Number of participants with DLTs |
1 Cycle (21 or 28 days)
|
|
Phase 1b: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: Overall response rate (ORR)
大体时间:Up to Approximately 60 Months or 5 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 60 Months or 5 Years
|
|
Phase 2: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: ORR
大体时间:Up to Approximately 60 Months or 5 Years
|
ORR per RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
大体时间:Up to Approximately 60 Months or 5 Years
|
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 60 Months or 5 Years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To characterize the pharmacokinetics (PK) properties of Sofe-M (LY4170156): Minimum Plasma Concentration (Cmin)
大体时间:First 4 Cycles (84 days)
|
PK: Cmin of Sofe-M (LY4170156) |
First 4 Cycles (84 days)
|
|
To characterize the PK properties of Sofe-M (LY4170156): Cmin with bevacizumab or carboplatin
大体时间:First 4 Cycles (Approximately 84 days)
|
PK: Cmin of Sofe-M (LY4170156) |
First 4 Cycles (Approximately 84 days)
|
|
To characterize the PK properties of Sofe-M (LY4170156): Cmin with pembrolizumab
大体时间:First 4 Cycles (84 days)
|
PK: Cmin of Sofe-M (LY4170156) |
First 4 Cycles (84 days)
|
|
To characterize the PK properties of Sofe-M (LY4170156): Area under the concentration versus time curve (AUC)
大体时间:First 4 Cycles (84 days)
|
PK: AUC of Sofe-M (LY4170156) |
First 4 Cycles (84 days)
|
|
To characterize the patient-reported outcomes (PRO) Common Terminology Criteria for Adverse Events (CTCAE) of Sofe-M (LY4170156)
大体时间:Up to Approximately 60 Months or 5 Years
|
PRO-CTCAE of Sofe-M (LY4170156) |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR)
大体时间:Up to Approximately 60 Months or 5 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR)
大体时间:Up to Approximately 60 Months or 5 Years
|
DOR per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years
|
DOR per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR)
大体时间:Up to Approximately 60 Months or 5 Years
|
TTR per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years
|
TTR per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS)
大体时间:Up to Approximately 60 Months or 5 Years
|
PFS per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years]
|
PFS per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years]
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR)
大体时间:Up to Approximately 60 Months or 5 Years
|
DCR per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
|
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years
|
DCR per investigator assessed RECIST 1.1 |
Up to Approximately 60 Months or 5 Years
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 呼吸道疾病
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 肠道肿瘤
- 直肠疾病
- 子宫疾病
- 生殖器疾病,女性
- 肺部疾病
- 内分泌腺肿瘤
- 胰腺疾病
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 宫颈疾病
- 癌,支气管癌
- 支气管肿瘤
- 子宫肿瘤
- 皮肤和结缔组织疾病
- 肺肿瘤
- 结直肠肿瘤
- 卵巢肿瘤
- 乳腺肿瘤
- 胰腺肿瘤
- 癌,非小细胞肺癌
- 宫颈肿瘤
- 三阴性乳腺肿瘤
- 子宫内膜肿瘤
- 氨基酸,肽和蛋白质
- 蛋白质
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- Azoles
- 抗体,单克隆,人源化
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 协调配合物
- 三轮唑
- 哌嗪
- 贝伐单抗
- 卡铂
- 伊曲康唑
- Pembrolizumab
其他研究编号
- 18863
- LOXO-FRA-24001 (其他标识符:Eli Lilly and Company)
- 2024-511238-11-00 (克蒂斯)
- J5E-OX-JZXA (其他标识符:Eli Lilly and Company)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 共享时间框架
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD 共享访问标准
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.